Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 9/20 | 0.43 |
| ▸ | GRK3 | P35626 | 5/20 | 0.42 |
| ▸ | GRK5 | P34947 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536140 | 0.80 | CYP17A1 (0.47) | GRK2GRK3GRK5ROCK2MEN1 | |
| SCHEMBL5539705 | 0.78 | GRK2 (0.56) | GRK2GRK3GRK5ROCK2LMNA | |
| SCHEMBL5329635 | 0.78 | GRK2 (0.55) | GRK2GRK3GRK5ROCK2MEN1 | |
| SCHEMBL5533048 | 0.76 | CA1 (0.57) | GRK2GRK3GRK5ROCK2KMT2A | |
| SCHEMBL5535879 | 0.75 | GRK2 (0.57) | GRK2GRK3GRK5ROCK2LMNA | |
| SCHEMBL14496447 | 0.75 | GRK2 (0.76) | GRK2GRK3GRK5ROCK2 | |
| SCHEMBL5545993 | 0.73 | GRK2 (0.59) | GRK2GRK3ROCK2LMNA | |
| SCHEMBL5537464 | 0.70 | CYP17A1 (0.39) | GRK2GRK3GRK5ROCK2MEN1 | |
| SCHEMBL31522633 | 0.68 | ACHE (0.58) | ACHELMNABCHEMEN1KMT2A | |
| SCHEMBL5533006 | 0.67 | GRK2 (0.64) | GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | GRK2 2/4885GRK3 4/4885GRK5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.